Zojwalla Naseem 4

4 · Olema Pharmaceuticals, Inc. · Filed Feb 4, 2026

AI-generated summary of this filing

Updated Feb 5, 2026

Olema (OLMA) CMO Naseem Zojwalla Receives Equity Awards

What Happened

Naseem Zojwalla, Chief Medical Officer of Olema Pharmaceuticals (OLMA), received two equity awards on February 2, 2026 totaling 356,250 derivative shares: 250,000 time‑based awards and 106,250 performance‑based awards. Each grant is reported at $0.00 per share (award/derivative), so no cash was exchanged.

Key Details

Transaction date: 2026-02-02; filing date: 2026-02-04 (appears timely — Form 4s are generally due within 2 business days).
Reported price: $0.00 per share; total reported cash value: $0.
Shares reported: 250,000 (time‑based) + 106,250 (performance‑based) = 356,250 derivative awards.
Shares owned after the transaction: not disclosed in this Form 4.
Footnote summary:
- F1 (time‑based): 25% of the option grant vests on Feb 2, 2027, then 1/48 of the total vests monthly thereafter, subject to continued service.
- F2 (performance‑based): The 106,250 awards vest only if Olema's stock reaches pre‑set price thresholds during one of two performance periods (Feb 2, 2026–Dec 31, 2029 and Feb 2, 2026–Dec 31, 2030). Vesting occurs after Compensation Committee certification of threshold achievement and is subject to continued service.
Transaction type code: A = Grant/Award (derivative security).

Context

These are equity awards (derivative/option‑style) granted as compensation — not open‑market purchases or sales — and do not represent immediate cash proceeds or sales of stock. Performance awards depend on stock‑price targets measured by a 30‑day average and on continued employment; time‑based awards vest over several years. For retail investors, grants signal potential future alignment of executive pay with company performance but do not by themselves indicate buying or selling pressure.

Form 4

Period: 2026-02-02

CHIEF MEDICAL OFFICER

Transactions

Award
Stock Option (Right to Buy)
[F1]
2026-02-02+250,000→ 250,000 total
Exercise: $25.65Exp: 2036-02-01→ Common Stock (250,000 underlying)
Award
Performance Stock Options (Right to Buy)
[F2]
2026-02-02+106,250→ 106,250 total
Exercise: $25.65Exp: 2036-02-01→ Common Stock (106,250 underlying)

Footnotes (2)

[F1]25% of the shares subject to the option vest on February 2, 2027, and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
[F2]The performance-based stock options will be eligible to vest during two distinct performance periods, each beginning on February 2, 2026 and ending on December 31, 2029 and December 31, 2030, respectively, based on the Issuer's stock price trading at certain pre-determined price thresholds as measured by the average closing price per share of the Issuer's stock over a consecutive thirty (30) day trading period during each such performance period. Once a price threshold is achieved, the portion of the award related to such threshold will vest upon the date set forth in the certification by the Compensation Committee certifying that such price threshold was achieved, subject to the Reporting Person's continuous service as of the applicable certification date.

Signature

/s/ Shawnte Mitchell, Attorney-in-Fact|2026-02-04

2 files